GlassScriptPhysician profile
Dong Won Kim
NPI 1831695204
$4,537.58
in general payments reported to CMS, 2019-2025
51 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2024: $1,648 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,087 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,087.49 |
| Education | $345.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $465.32 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Aveo Pharmaceuticals, INC. | $277.32 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $263.01 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $257.52 | 2024-2025 | Calquence, Lynparza, Enhertu |
| Alexion Pharmaceuticals, INC. | $226.58 | 2022-2024 | Soliris, Ultomiris |
| Merck Sharp & Dohme LLC | $222.91 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $217.78 | 2024-2025 | |
| Daiichi Sankyo INC. | $194.61 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $172.66 | 2024-2025 | Jemperli, Zejula |
| Lilly USA, LLC | $169.07 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $125.14 | 2024-2025 | |
| Exelixis INC. | $123.53 | 2024-2025 | Cabometyx |
| Array Biopharma INC | $108.63 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $103.19 | 2024-2025 | Besremi |
| Adc Therapeutics America, INC. | $92.52 | 2024-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $92.19 | 2025 | Xt Cdx |
| Eisai INC. | $84.95 | 2024-2025 | |
| Taiho Oncology, INC. | $84.53 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $79.50 | 2024-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $77.40 | 2024-2025 | Libtayo |
| Abbvie INC. | $70.86 | 2024-2025 | |
| Genmab U.S., INC. | $68.77 | 2025 | Epkinly |
| Sobi, INC | $61.50 | 2025 | |
| Pharmacosmos Therapeutics INC. | $52.19 | 2024-2025 | Monoferric |
| Tersera Therapeutics LLC | $51.91 | 2025 | Xermelo, Zoladex |
| Beone Medicines USA, INC. | $51.42 | 2025 | Brukinsa |
| Amgen INC. | $51.02 | 2022-2025 | Uplizna, Prolia, Evenity |
| Rigel Pharmaceuticals, INC. | $46.75 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Genentech USA, INC. | $43.40 | 2024-2025 | Venclexta, Gazyva |
| Stemline Therapeutics INC. | $43.15 | 2025 | Orserdu |
| Emd Serono, INC. | $42.63 | 2025 | |
| Genzyme Corporation | $37.99 | 2025 | |
| Incyte Corporation | $37.49 | 2024-2025 | Jakafi, Niktimvo |
| Karyopharm Therapeutics INC. | $31.94 | 2024 | Xpovio |
| Menarini Silicon Biosystems, INC. | $31.85 | 2025 | |
| Blueprint Medicines Corporation | $31.20 | 2025 | Ayvakit |
| Puma Biotechnology, INC. | $31.10 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $30.70 | 2024-2025 | Orgovyx |
| Janssen Pharmaceuticals, INC | $29.93 | 2025 | Erleada |
| Gilead Sciences, INC. | $27.59 | 2025 | Trodelvy |
| Iovance Biotherapeutics, INC. | $27.17 | 2025 | Amtagvi |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Kyowa Kirin, INC. | $22.88 | 2024 | Poteligeo |
| Spectrum Pharmaceuticals INC. | $21.96 | 2024 | Rolvedon |
| Springworks Therapeutics, INC. | $20.78 | 2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $20.61 | 2025 | |
| Astellas Pharma US INC | $20.12 | 2024 | Vyloy |
| Beigene USA, INC. | $18.99 | 2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.81 | 2024 | Fruzaqla |
| Adaptive Biotechnologies Corporation | $17.11 | 2025 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $14.76 | 2025 | Tgct, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.